KR20060134179A - 트리(사이클로) 치환된 아미드 화합물 - Google Patents

트리(사이클로) 치환된 아미드 화합물 Download PDF

Info

Publication number
KR20060134179A
KR20060134179A KR1020067022240A KR20067022240A KR20060134179A KR 20060134179 A KR20060134179 A KR 20060134179A KR 1020067022240 A KR1020067022240 A KR 1020067022240A KR 20067022240 A KR20067022240 A KR 20067022240A KR 20060134179 A KR20060134179 A KR 20060134179A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067022240A
Other languages
English (en)
Korean (ko)
Inventor
매튜 피페
Original Assignee
프로시디온 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로시디온 리미티드 filed Critical 프로시디온 리미티드
Publication of KR20060134179A publication Critical patent/KR20060134179A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067022240A 2004-04-21 2005-04-19 트리(사이클로) 치환된 아미드 화합물 Ceased KR20060134179A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56417104P 2004-04-21 2004-04-21
US60/564,171 2004-04-21
US60107704P 2004-08-12 2004-08-12
US60/601,077 2004-08-12

Publications (1)

Publication Number Publication Date
KR20060134179A true KR20060134179A (ko) 2006-12-27

Family

ID=34965439

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022240A Ceased KR20060134179A (ko) 2004-04-21 2005-04-19 트리(사이클로) 치환된 아미드 화합물

Country Status (15)

Country Link
US (1) US20080242869A1 (https=)
EP (1) EP1740560A1 (https=)
JP (1) JP2007533722A (https=)
KR (1) KR20060134179A (https=)
AU (1) AU2005235798A1 (https=)
BR (1) BRPI0510163A (https=)
CA (1) CA2563192A1 (https=)
EA (1) EA012204B1 (https=)
IL (1) IL178473A0 (https=)
MA (1) MA28545B1 (https=)
MX (1) MXPA06012008A (https=)
NO (1) NO20065260L (https=)
NZ (1) NZ550567A (https=)
WO (1) WO2005103021A1 (https=)
ZA (1) ZA200608489B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
AU2005229415B2 (en) 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
AU2005271016A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
AU2009205070A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
SI2275414T1 (sl) * 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
CN102245574A (zh) * 2008-12-08 2011-11-16 欧洲筛选有限公司 用于治疗代谢疾病的化合物、药物组合物以及方法
UA104742C2 (uk) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
JP2013522294A (ja) 2010-03-18 2013-06-13 タケダ カリフォルニア インコーポレイテッド ２−アミノ−５−フルオロチアゾールの製造プロセス

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
SI1169312T1 (en) * 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU778036B2 (en) * 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
MXPA03000365A (es) * 2000-07-20 2003-05-27 Hoffmann La Roche Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa.
WO2002046173A1 (en) * 2000-12-06 2002-06-13 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
EP1501815B1 (en) * 2002-04-26 2006-11-22 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe

Also Published As

Publication number Publication date
EA012204B1 (ru) 2009-08-28
CA2563192A1 (en) 2005-11-03
BRPI0510163A (pt) 2007-10-02
MA28545B1 (fr) 2007-04-03
NO20065260L (no) 2006-11-21
MXPA06012008A (es) 2007-01-25
WO2005103021A1 (en) 2005-11-03
EA200601747A1 (ru) 2007-04-27
AU2005235798A1 (en) 2005-11-03
JP2007533722A (ja) 2007-11-22
ZA200608489B (en) 2008-06-25
US20080242869A1 (en) 2008-10-02
EP1740560A1 (en) 2007-01-10
IL178473A0 (en) 2007-02-11
NZ550567A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
KR20060134179A (ko) 트리(사이클로) 치환된 아미드 화합물
EP1594867B1 (en) Phenylacetamides and their use as glucokinase modulators
KR100890695B1 (ko) 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
JP4621198B2 (ja) トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
EP1948622A1 (en) Tricyclo substituted amides as glucokinase modulators
JP2006517590A5 (https=)
JP5620393B2 (ja) 脳梗塞治療薬
CN100567276C (zh) 三（环）取代的酰胺类化合物
CN1809561B (zh) 苯基乙酰胺及它们作为葡糖激酶调节剂的应用
HK1082507A1 (en) Phenylacetamides and their use as glucokinase modulators
HK1082507B (en) Phenylacetamides and their use as glucokinase modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100419

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20111216

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120522

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20111216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I